Esketamine DPI - low dose + Esketamine DPI - medium dose + Esketamine DPI - high dose + Placebo DPI

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Feb 25, 2019 → Apr 24, 2020

NCT ID

NCT03965858

About Esketamine DPI - low dose + Esketamine DPI - medium dose + Esketamine DPI - high dose + Placebo DPI

Esketamine DPI - low dose + Esketamine DPI - medium dose + Esketamine DPI - high dose + Placebo DPI is a phase 2 stage product being developed by Celon Pharma for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03965858. Target conditions include Major Depressive Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder were approved

Approved (20) Terminated (0) Active (0)

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅DuloxetineEli LillyApproved

✅duloxetineEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03965871	Phase 2	Completed	Mar 28, 2019	Feb 19, 2021	Bipolar Depression
NCT03965858	Phase 2	Completed	Feb 25, 2019	Apr 24, 2020	Major Depressive Disorder

Competing Products

20 competing products in Major Depressive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	26
LY2216684	Eli Lilly	Phase 1	29
LY2216684	Eli Lilly	Phase 1	29
Duloxetine	Eli Lilly	Phase 3	40
LY2216684 + Digoxin	Eli Lilly	Phase 1	29
Duloxetine + Paroxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
Mirtazapine Tablets	Sun Pharmaceutical	Approved	43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Pramipexole ER + Escitalopram	Cipla	Phase 2	42
LY2216684 + Sertraline	Eli Lilly	Phase 1	29
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	29
LY2216684 + SSRI	Eli Lilly	Phase 3	40